Efficacy and Safety of Low-Dose Versus Standard-Dose Alteplase to Treat High-Risk Pulmonary Embolism

Author(s): Ariel Haber, PharmD, BCCCP, Ada Selina Jutba, PharmD, BCCCP, Haya Kaseer, PharmD, BCCCP, Moustafa Younis, MD, MSCR, and Ali Ataya, MD, MBA

Contact Hours 1.00

CERP A 1.00

Pharmacology Hours 1.00

Expires Nov 01, 2029

Topics: Pulmonary, Hematology/Oncology

Fees
Member: Free
NonMember: $10.00

Added to Collection

Activity Summary

Before you Begin

1. Reflect on the following question: What new knowledge or perspective do you hope to gain from this activity?

2. Review: Implicit Bias and its Impact on Patient Outcomes (License requirement for California)

Description

This article examines the ongoing debate over the optimal alteplase dose for patients with high-risk pulmonary embolism (PE), a condition associated with the highest short-term mortality among hospitalized patients. While alteplase is an approved thrombolytic therapy for PE, uncertainty remains regarding whether low-dose (50 mg) or standard-dose (100 mg) treatment provides the best balance of efficacy and safety. Using contemporary definitions of high-risk PE, including right ventricular dysfunction and hemodynamic instability, the study compares clinical outcomes between dosing strategies. The findings provide important insights for critical care clinicians managing patients with life-threatening PE and may help inform thrombolytic treatment decisions in this high-risk population.

Objectives

  • Define high-risk pulmonary embolism (PE).
  • Analyze the impact of alteplase dosing on hemodynamic stability in high-risk PE.
  • Evaluate the association between age and alteplase dosing.

Continuing Education Disclosure Statement

Criteria for Awarding Contact Hours

Learners must complete the entire activity and the associated evaluation AND read Implicit Bias impacts patient outcomes. No partial credit will be awarded.

Accreditation

American Association of Critical-Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Provider approved by the California Board of Registered Nursing, Provider number CEP 1036, for {contactHours} contact hours.

Disclosures

The Nurse Planner has determined that no individuals with the ability to control content of this activity have relevant relationships with ineligible companies.

Activities with pharmacotherapeutic credit are to assist the APRN in fulfilling their education requirements for licensure and certification renewals.

Refund Policy

Continuing Education Activities are nonrefundable.